Q2 2026 Earnings Deck
August 6th, 2026

Cryoport
Enabling the Future of Medicine

Forward Looking Statements

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's anticipation that it will benefit from its operating leverage, the Company's belief that it is well positioned to further expand margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company's expectation that upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport – Trusted Partner to Life Sciences Companies

Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions

Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as:

- Cell therapies
- Gene therapies
- Human and animal reproductive materials

The recognized supply chain leader in supporting the C&GT market

The leading manufacturer of cryogenic systems and accessories in the world

One of the largest biorepositories in the U.S.

Cryoport
Enabling the Future of Medicine

Cryoport Systems

MVE Biological Solutions

CRYOGENE

Cryoport, Inc. (CYRX) operates as an operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry

Cryoport Snapshot – By the Numbers

Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain

$49M
+8% Organic Growth
Q2 FY2026
Revenue

$192-$196M
+9-11% Organic Growth
FY2026
Updated Revenue Guidance

46.6%
Q2 FY2026
Gross Margin

$0.4M
$1.3M Improvement YoY
Q2 FY2026 Adjusted
EBITDA

779
Active CGT
Clinical Trials

25%
Q2 BioStorage/BioServices
Growth YoY

22
Commercial CGTs
Supported

$397M
Q2 FY2026 Cash
($185M senior convertible debt to be repaid 12/2026)

Note: Number of active CGT clinical trials and commercial CGTs supported as of June 30, 2026.

Revenue from supporting Commercial Cell and Gene Therapies
Q1 2024 through Q2 2026



Q2 Life Sciences Services Overview

BioLogistics Solutions Revenue
($ in millions)



BioStorage/BioServices Revenue
($ in millions)



Q2 2026 Revenue Drivers

Strong double-digit growth across the platform of services



Cell Therapy Market Growing 28% Through 2030
(Includes Cell and CAR-T Therapies)



Source: Evaluate Pharma

CGT Industry Funding ($ bil.)



Source: Alliance for Regenerative Medicine

Growth in U.S. CGT Claims and Treatment Centers
(2018 vs. 2025)





Source: Alliance for Regenerative Medicine Whitepaper - Cell & Gene Therapy Expansion: The Evolution of CGT Delivery in the U.S. – June 2026

Patients First: Supporting the Therapies of Tomorrow



Trial count as of the end of the respective periods

Supporting 23 Commercial Cell and Gene Therapies Globally

- Abecma (idecabtagene vicleucel) suspension for IV infusion
- アクーゴ AKUUGO®
- AMTAGVI™ (lifileucel)
- Breyanzi
- Carvykti™ (ciltacabtagene autoleucel)
- TUDRIQEV
- TREGZI™ (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) Suspension for IV infusion
- casgevy™ (exagamglogene autotemcel) suspension for IV infusion
- EBVALLO®▼ tabelecleucel
- Elevidys delandistrogene moxeparvovec-rokl suspension for intravenous infusion
- libmeldy™ (atidarsagene autotemcel)
- Lyfgenia™ (lovotibeglogene autotemcel) suspension for IV infusion
- Ryoncil® (remestemcel-L-rknd)
- skysona™ (elivaldogene autotemcel) suspension for IV infusion
- Strimvelis®▼
- TECARTUS® (brexucabtagene autoleucel) Suspension for IV infusion
- Tecelra® afamitresgene autoleucel
- KRESLADI™ marnetegragene autotemcel
- YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion
- Zemcelpro®
- zevaskyn™ (prademagene zamikeracel) gene-modified cellular sheets
- zynteglo® (betibeglogene autotemcel) suspension for IV infusion
- Waskyra etuvetidigene autotemcel

Cryoport, Inc. Global Locations

Paris, FRANCE (BioServices Q4-2026)

Global Supply Chain Center
55,000 sq. ft.

Santa Ana, USA (BioLogistics Q4-2026)

Global Supply Chain Center
94,000 sq. ft.

Cryoport Supported Clinical Trials by Phase

Clinical Trials	June 30,		
	2024	2025	2026
Phase 1	286	304	316
Phase 2	322	342	369
Phase 3	76	82	94
Total	**684**	**728**	**779**

Cryoport Supported Clinical Trials by Region

Clinical Trials	June 30,		
	2024	2025	2026
Americas	525	556	579
EMEA	114	124	145
APAC	45	48	55
Total	**684**	**728**	**779**

Cryoport, Inc. and Subsidiaries
Revenue

(in thousands)	Three Months Ended June 30, (unaudited)			Six Months Ended June 30, (unaudited)		
	2026	2025	% Change	2026	2025	% Change
Life Sciences Services	$ 27,969	$ 24,369	15%	$ 54,867	$ 47,234	16%
BioLogistics Solutions	22,359	19,874	13%	44,027	38,404	15%
BioStorage/BioServices	5,610	4,495	25%	10,840	8,830	23%
Life Sciences Products	$ 21,002	$ 21,085	0%	$ 41,902	$ 39,260	7%
Total Revenue	$ 48,971	$ 45,454	8%	$ 96,769	$ 86,494	12%

Cryoport, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations

	Three Months Ended June 30, (unaudited)		Six Months Ended June 30, (unaudited)	
(in thousands, except share and per share data)	2026	2025	2026	2025
Revenue				
Life Sciences Services revenue	$ 27,969	$ 24,369	$ 54,867	$ 47,234
Life Sciences Products revenue	21,002	21,085	41,902	39,260
Total revenue	48,971	45,454	96,769	86,494
Cost of revenue:				
Cost of services revenue	14,008	12,449	27,755	24,369
Cost of products revenue	12,139	11,628	24,277	22,107
Total cost of revenue	26,147	24,077	52,032	46,476
Gross margin	22,824	21,377	44,737	40,018
Operating costs and expenses:				
Selling, general and administrative	28,011	26,908	55,631	48,809
Engineering and development	4,852	4,118	8,759	8,052
Total operating costs and expenses:	32,863	31,026	64,390	56,861
Loss from operations	(10,039)	(9,649)	(19,653)	(16,843)
Other income (expense):				
Investment income	3,132	1,466	6,222	3,039
Interest expense	(518)	(618)	(950)	(1,201)
Other expense, net	(325)	(2,939)	(2,693)	(3,239)
Loss before provision for income taxes	(7,750)	(11,740)	(17,074)	(18,244)
Provision for income taxes	(505)	(274)	(613)	(508)
Loss from continuing operations	$ (8,255)	$ (12,014)	$ (17,687)	$ (18,752)
Income (loss) from discontinued operations, net	-	120,883	(1,112)	115,640
Net income (loss)	$ (8,255)	$ 108,869	$ (18,799)	$ 96,888
Paid-in-kind dividend on Series C convertible preferred stock	(2,000)	(2,000)	(4,000)	(4,000)
Net income (loss) attributable to common stockholders	$ (10,255)	$ 106,869	$ (22,799)	$ 92,888
Net income (loss) per share attributable to common stockholders - basic and diluted	$ (0.20)	$ 2.13	$ (0.45)	$ 1.85
Weighted average common shares issued and outstanding - basic and diluted	50,442,796	50,257,112	50,173,730	50,102,918

Gross margin - Total [%]	46.6%	47.0%	46.2%	46.3%
Gross margin - Services [%]	49.9%	48.9%	49.4%	48.4%
Gross margin - Products [%]	42.2%	44.9%	42.1%	43.7%

Cryoport, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in thousands)	June 30, 2026 (unaudited)	December 31, 2025
Current assets		
Cash and cash equivalents	$ 269,267	$ 250,494
Short-term investments	127,426	160,714
Accounts receivable, net	36,454	33,359
Inventories	21,506	23,188
Prepaid expenses and other current assets	5,550	8,419
Total current assets	460,203	476,174
Property and equipment, net	94,516	85,448
Operating lease right-of-use assets	40,323	39,720
Intangible assets, net	135,992	138,082
Goodwill	22,068	22,400
Deposits	2,038	2,092
Deferred tax assets	1,064	1,073
Total assets	$ 756,204	$ 764,989
Current liabilities		
Accounts payable and other accrued expenses	$ 16,247	$ 15,283
Accrued compensation and related expenses	12,186	12,980
Deferred revenue	1,720	943
Current portion of operating lease liabilities	3,937	4,133
Current portion of finance lease liabilities	448	422
Current portion of convertible senior notes, net	185,687	185,094
Current portion of notes payable	159	163
Current portion of contingent consideration	652	-
Total current liabilities	221,036	219,018
Notes payable, net	985	1,087
Operating lease liabilities, net	40,076	39,078
Finance lease liabilities, net	726	741
Deferred tax liabilities	1,850	1,354
Other long-term liabilities	832	444
Contingent consideration	-	629
Total liabilities	265,505	262,351
Total stockholders' equity	490,699	502,638
Total liabilities and stockholders' equity	$ 756,204	$ 764,989

Cryoport, Inc. and Subsidiaries
Reconciliation of GAAP loss from continuing operations to adjusted EBITDA
(unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
(in thousands)				
GAAP loss from continuing operations	$ (8,255)	$ (12,014)	$ (17,687)	$ (18,752)
Non-GAAP adjustments to loss:				
Depreciation and amortization expense	6,589	6,249	12,991	12,383
Acquisition and integration costs	—	30	—	31
Cost reduction initiatives	140	266	140	482
Investment income	(3,132)	(1,466)	(6,222)	(3,039)
Unrealized (gain) loss on investments	(212)	1,082	1,893	1,275
Foreign currency loss	651	2,002	1,105	2,247
Interest expense, net	518	618	950	1,201
Stock-based compensation expense	2,402	2,045	4,797	5,109
Change in fair value of contingent consideration	27	—	42	(5,178)
Income taxes	505	274	613	508
Other adjustments	1,142	—	1,142	—
Adjusted EBITDA from continuing operations	$ 375	$ (914)	$ (236)	$ (3,733)

Driving Bottom-Line Improvement

46.6%

Gross Margin from Continuing Operations

$0.4M

Adjusted EBITDA from Continuing Operations

$397M

Cash and Short-Term Investment